Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
about
Adoptive T cell therapy for cancer in the clinicStructures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell RecognitionMonitoring of the Immune Dysfunction in Cancer PatientsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionStrategies to genetically engineer T cells for cancer immunotherapy.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.Adoptive T cell immunotherapy for cancer.Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsDeterminants of public T cell responses.Trial Watch: Adoptive cell transfer immunotherapy.The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.Adoptive T-cell transfer in cancer immunotherapy.Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive TumorsAdhesion molecules in cutaneous immunity.Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapyImmune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesIdentification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma.New frontiers in cell-based immunotherapy of cancer.Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination.Is antigen specificity the key to efficient adoptive T-cell therapy?Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes.A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation.PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro.Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context.Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
P2860
Q24680405-45B2FCAA-3332-4431-B523-C2D706515A4EQ27647534-2742AC3D-32E0-408F-A44E-B228AF27C922Q28072712-63DFE293-2B52-4D6A-BB92-FEBA490638F1Q28078539-8BD35BE4-6FE6-4BD4-98AF-12AE08148D38Q33378044-28915CBD-24C2-463B-9F15-38B6645642F5Q33635226-EAD2E6F3-4715-467F-967B-E5820443E09BQ33655849-CDFD193A-27C6-4765-8381-1891DC6837EEQ33750205-9A45EF38-FA7B-4A48-8CC3-EFBC5C9F0E65Q34111789-35B6A3AD-6B45-40CA-B317-5C1C45473281Q34391263-F3A2A55B-00C1-4E96-9FFE-4DD4EF7B9D71Q35044333-33A973A6-43BE-4069-A998-0B024DD99A7BQ35081485-B17881D5-13A7-46CE-889D-7F794D5DD35AQ35108299-0D7275B4-2029-48BC-8544-F9D6428F0BEFQ35673240-596D09B9-1AE3-45AB-AB4B-DB7914D58A5AQ35958856-BCCBE1F9-8298-4071-B71C-9F843046121AQ36057432-5155D7E1-BA36-477D-B6C7-2975E4773B99Q36429079-3149B761-C9C3-46A6-97C9-DF74E0AC1EE9Q36471818-E3993283-2CD8-446F-88BA-9BEDCC37D017Q36807231-A506E318-CBBF-48E0-907E-BA165BD0ABF6Q36875875-C9AB35CB-DAF4-43F6-B231-7F4F1D8F3A01Q36960476-C82C3B25-4939-4BF1-A851-6F525134F175Q37137360-1A5BC7CD-026E-4583-AFE1-7A7897C8112BQ37160648-56C80729-F4A6-4F82-B144-1F667ECBA3C3Q37249766-424F2181-3ABC-47DD-9784-14F82DEE7002Q37481361-59F376ED-9502-4C53-B09B-B55FD2BC57E5Q37837483-D57F147A-9A3F-4CD4-89C2-74338C3C7D04Q37861214-C1417436-8109-4D07-B4D0-733C6EFAC9B7Q37986559-A1191ACC-86EE-4ECF-8C54-9066F226559DQ38943954-767FB0B4-F09F-46E6-BBCB-F368FD22A30CQ39946673-6AB68B9D-EF53-4C58-8ACA-1CDECA329013Q40081629-28FD8042-6A46-425E-AC25-504A04132297Q40103369-88E1D74D-42FB-404C-B7E6-8C4855AA4727Q42319060-F1F0781D-3F57-4CB0-9846-681EB69121C5Q42615546-4AB73257-BE01-4B10-A815-E8FF06360EF8Q42632718-F99116D2-905E-4ED6-9B74-3B34A66BC2E9Q43147458-669C7EFF-DC6B-4515-BBB1-1BB4A9145386Q44134119-66C8C96C-5B41-4DCD-8D10-96B61540C04CQ50940546-7023FB96-FBDC-4D0C-8062-BBB0377D0F43Q51886628-59135E72-7E40-4AB2-94DF-4272D2D4693FQ52626852-2D693293-1B1D-4389-AB11-7B3E68D82D4B
P2860
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@ast
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@en
type
label
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@ast
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@en
prefLabel
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@ast
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@en
P2093
P1476
Adoptive transfer of tumor-rea ...... onal Melan-A-specific T cells.
@en
P2093
Amir Khammari
Annick Lim
Brigitte Dreno
Brigitte Lemercier
Catherine Rabu
Francine Jotereau
François Lang
Klara Echasserieau
Marie-Christine Pandolfino
Marie-Lise Gougeon
P304
P356
10.4049/JIMMUNOL.175.7.4797
P407
P577
2005-10-01T00:00:00Z